Ocular hypertension and intraocular pressure asymmetry after intravitreal injection of anti-vascular endothelial growth factor agents

Ophthalmic Surgery Lasers and Imaging Retina

Volumn 44, Issue 5, 2013, Pages 460-464

  Pershing, Suzann ^a,b   Bakri, Sophie J ^c   Moshfeghi, Darius M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG EFFECT; EYE; FEMALE; FOLLOW UP; GLAUCOMA; GOLDMANN APPLANATION TONOMETER; HUMAN; INJECTION; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; PATIENT MONITORING; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG EFFECTS; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; VERY ELDERLY; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; BLOOD PRESSURE MEASUREMENT; CENTRAL RETINA VEIN OCCLUSION; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DIAGNOSTIC TEST; DRUG EFFICACY; DRUG SAFETY; EYE EXAMINATION; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; OCULAR HYPERTENSION; RETROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84884916885     PISSN: 23258160     EISSN: 23258179     Source Type: Journal    
DOI: 10.3928/23258160-20130909-07     Document Type: Article

References (43)

1. Rosenfeld PJ, Brown DM, Heier J.S., et al Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006; 355(14): 1419-1431. (Pubitemid 44511557)
2. Brown DM, Kaiser PK, Michels M, et al Ranibizumab versus verte-porfin for neovascular age-related macular degeneration. N Engl J Med. 2006; 355(14): 1432-1444. (Pubitemid 44511558)
3. Rosenfeld PJ, Moshfeghi AA, Puliafito CA Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005; 36(4): 331-335. (Pubitemid 41073112)
4. Fung AE, Lalwani GA, Rosenfeld P.J., et al An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibi-zumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007; 143(4): 566-583.
5. Avery RL, Pieramici DJ, Rabena M.D., Castellarin AA, Nasir MA, Gi-ust MJ.Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006; 113(3): 363-372.
6. Regillo CD, Brown DM, Abraham P, et al Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol. 2008; 145(2): 239-248.
7. Abraham P, Yue H, Wilson L. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am J Ophthalmol. 2010; 150(3): 315-324.
8. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol. 2006; 90(11): 1344-1349. (Pubitemid 44702055)
9. Peyman GA, Lad EM, Moshfeghi DM Intravitreal injection of therapeutic agents. Retina. 2009; 29(7): 875-912.
10. Carvounis PE, Kopel AC, Benz MS Retinal pigment epithelium tears following ranibizumab for exudative age-related macular degeneration. Am J Ophthalmol. 2007; 143(3): 504-505.
11. Chan CK, Meyer CH, Gross J.G., et al Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration. Retina. 2007; 27(5): 541-551. (Pubitemid 46905143)
12. Chang LK, Flaxel CJ, Lauer A.K., Sarraf D. RPE tears after pegap-tanib treatment in age-related macular degeneration. Retina. 2007; 27(7): 857-863. (Pubitemid 47479380)
13. Lee GK, Lai TY, Chan W.M., Lam DS Retinal pigment epithelial tear following intravitreal ranibizumab injections for neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2007; 245(8): 1225-1227. (Pubitemid 47034347)
14. Ronan SM, Yoganathan P, Chien F.Y., et al Retinal pigment epithelium tears after intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Retina. 2007; 27(5): 535-540. (Pubitemid 46905142)
15. Amselem L, Pulido JS, Diaz-Llopis M, Cervera E., Montero J. Retinal pigment epithelial tear following ranibizumab use. Eye (Lond). 2007; 21(6): 846-847. (Pubitemid 46909199)
16. Bakri SJ, Kitzmann AS Retinal pigment epithelial tear after intravit-real ranibizumab. Am J Ophthalmol. 2007; 143(3): 505-507. (Pubitemid 46273349)
17. Meyer CH, Mennel S, Schmidt J.C., Kroll P. Acute retinal pigment epithelial tear following intravitreal bevacizumab (Avastin) injection for occult choroidal neovascularisation secondary to age related macular degeneration. Br J Ophthalmol. 2006; 90(9): 1207-1208. (Pubitemid 44351161)
18. Singh R.P., Sears JE Retinal pigment epithelial tears after pegaptanib injection for exudative age-related macular degeneration. Am J Oph-thalmol. 2006; 142(1): 160-162. (Pubitemid 43946807)
19. Bakri SJ, McCannel CA, Edwards A.O., Moshfeghi DM Persistent ocular hypertension following intravitreal ranibizumab. Graefes Arch Clin Exp Ophthalmol. 2008; 246(7): 955-958.
20. Adelman RA, Zheng Q, Mayer HR Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections. J Ocul Pharmacol Ther. 2010; 26(1): 105-110.
21. Kahook MY, Kimura AE, Wong L.J., Ammar DA, Maycotte MA, Mandava N. Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections. Ophthalmic Surg Lasers Imaging. May-Jun 2009; 40(3): 293-295.
22. Skalicky SE, Ho I, Agar A., Bank A. Glaucoma filtration surgery following sustained elevation of intraocular pressure secondary to intra-vitreal anti-VEGF injections. Ophthalmic Surg Lasers Imaging. 2012; 43(4): 328-334.
23. Mathalone N, Arodi-Golan A, Sar S., et al Sustained elevation of intraocular pressure after intravitreal injections of bevacizumab in eyes with neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2012; 250(10): 1435-1440.
24. Aref AA. Management of immediate and sustained intraocular pressure rise associated with intravitreal antivascular endothelial growth factor injection therapy. Curr Opin Ophthalmol. 2012; 23(2): 105-110
25. Tseng JJ, Vance SK, Della Torre KE, et al. Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. J Glaucoma. 2012; 21(4): 241-247.
26. Good TJ, Kimura AE, Mandava N, Kahook MY Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol. 2011; 95(8): 1111-1114.
27. Hoang QV, Mendonca LS, Della Torre KE, et al Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endo-thelial growth factor injections. Ophthalmology. 2012; 119(2): 321-326.
28. Choi DY, Ortube MC, McCannel C.A., et al Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibi-zumab, and pegaptanib. Retina. 2011; 31(6): 1028-1035.
29. Bakri SJ, Pulido JS, McCannel C.A., Hodge DO, Diehl N, Hillemeier J. Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye (Lond). 2009; 23(1): 181-185.
30. Frenkel M.P., Haji SA, Frenkel RE Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after in-travitreal injections. Arch Ophthalmol. 2010; 128(12): 1523-1527.
31. Frenkel RE, Mani L, Toler A.R., Frenkel M P. Intraocular pressure effects of pegaptanib (Macugen) injections in patients with and without glaucoma. Am J Ophthalmol. 2007; 143(6): 1034-1035. (Pubitemid 46764645)
32. Bakri S. Intraocular pressure in eyes receiving monthly ranibizumab: analysis of data from the MARINA and ANCHOR trials. Paper presented at: Macula Society meeting; February 24-27, 2010; Tucson, AZ.
33. Bakri SJ, Moshfeghi DM, Rundle A, et al IOP in eyes treated with monthly ranibizumab: A post hoc analysis of data from the MARINA and ANCHOR trials. Paper presented at: American Academy of Ophthalmology meeting; October 15, 2010; Chicago, IL.
34. Bakri et al. Paper presented at: American Academy of Ophthalmology meeting; October 2011; Orlando, FL.
35. Hoang QV, Tsuang AJ, Gelman R, et al Clinical predictors of sustained intraocular pressure elevation due to intravitreal anti-vascular endothelial growth factor therapy. Retina. 2013; 33(1): 179-187.
36. Wehrli SJ, Tawse K, Levin M.H., Zaidi A., Pistilli M, Brucker AJ A lack of delayed intraocular pressure elevation in patients treated with intravitreal injection of bevacizumab and ranibizumab. Retina. 2012; 32(7): 1295-1301.
37. Bakri SJ, Moshfeghi DM, Rundle A, et al IOP in eyes treated with monthly ranibizumab: A post hoc analysis of data from the MARINA and ANCHOR trials. Presented as a scientific paper at the AAO Annual Meeting; 15 October 2010; Chicago, IL, USA.
38. Gismondi M, Salati C, Salvetat M.L., et al Short-term effect of intra-vitreal injection of Ranibizumab (Lucentis) on intraocular pressure. J Glaucoma. 2009; 18: 658-661.
39. Kim JE, Mantravadi AV, Hur E.Y., Covert DJ Short-term intraocular pressure changes immediately after intravitreal injections of an-tivascular endothelial growth factor agents. Am J Ophthalmol. 2008; 146: 930-934.
40. Hollands H, Wong J, Bruen R., et al Short-term intraocular pressure changes after intravitreal injection of bevacizumab. Can J Ophthalmol. 2007; 42: 807-811.
41. Mojica G, Hariprasad SM, Jager R.D., Mieler W F. Short-term intraocular pressure trends following intravitreal injections of ranibizumab (Lucentis) for the treatment of wet age-related macular degeneration. Br J Ophthalmol. 2008; 92: 584. (Pubitemid 351498004)
42. Theoulakis PE, Lepidas J, Petropoulos I.K., Livieratou A., Brinkmann CK, Katsimpris JM Effect of brimonidine/timolol fixed combination on preventing the short-term intraocular pressure increase after intravitreal injection of ranibizumab. Klin Monbl Augenheilkd. 2010; 227: 280-284.
43. Sniegowski M, Mandava N, Kahook MY Sustained intraocular pressure elevation after intravitreal injection of bevacizumab and ranibi-zumab associated with trabeculitis. Open Ophthalmo Jl. 2010; 4: 28-29.